NKTX (Nkarta) Forward PE Ratio : 0.00 (As of Jan. 18, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Nkarta Forward PE Ratio?

Nkarta's Forward PE Ratio for today is 0.00.

Nkarta's PE Ratio without NRI for today is 0.00.

Nkarta's PE Ratio (TTM) for today is 0.00.

Nkarta Forward PE Ratio Historical Data

The historical data trend for Nkarta's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nkarta Forward PE Ratio Chart

Nkarta Annual Data

Trend

Forward PE Ratio

Nkarta Quarterly Data

Forward PE Ratio

Competitive Comparison of Nkarta's Forward PE Ratio

For the Biotechnology subindustry, Nkarta's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nkarta's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nkarta's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Nkarta's Forward PE Ratio falls into.

Nkarta Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Nkarta (NAS:NKTX) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

Nkarta Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Nkarta's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Nkarta Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nkarta Inc (NAS:NKTX) » Definitions » Forward PE Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1150 Veterans Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.nkartatx.com

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Executives

Alicia J. Hager	officer: Chief Legal Officer	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Paul J Hastings	director, officer: See Remarks	61 HARTFORD STREET, SAN FRANCISCO CA 94114
David Shook	officer: Chief Medical Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Ralph Brandenberger	officer: Sr. VP, Technical Operations	6000 SHORELINE COURT, SUITE 102, SAN FRANCISCO CA 94080
James Trager	officer: Chief Scientific Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Simeon George	director	161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alyssa Levin	officer: See Remarks	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Nadir Mahmood	officer: Chief Business Officer	6000 SHORELINE COURT, SUITE 102, SOUTH SAN FRANCISCO CA 94080
Angela Thedinga	director	C/O ADVERUM BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, MENLO PARK CA 94025
Ra Capital Nexus Fund, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kanya Rajangam	officer: Chief Medical Officer	C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James E Flynn	10 percent owner, other: Possible Member of 10% Group	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900